Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-1 Subtype C gp140 vaccine + MF59
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HIV-1 Subtype C gp140 vaccine + MF59 is an experimental vaccine regimen developed for the prevention of HIV-1 infection. It consists of a recombinant gp140 protein derived from a subtype C HIV-1 strain (specifically the TV1 isolate) formulated with the MF59 oil-in-water emulsion adjuvant. The gp140 protein is a truncated form of the HIV-1 envelope glycoprotein that includes the gp120 subunit and the extracellular domain of the gp41 subunit, designed to mimic the native trimeric envelope spike and elicit neutralizing antibodies. MF59 is used to enhance the magnitude and breadth of the immune response. This vaccine candidate has been evaluated in Phase 1 clinical trials, such as HVTN 048, to assess its safety and immunogenicity in healthy adults, including those previously primed with subtype B envelope vaccines.
- Other names
- Sub C gp140 VaccineHIV-1 Subtype C gp140 Vaccine With MF59 AdjuvantHIV1 Subtype C gp140 Vaccine With MF59 AdjuvantHIV 1 Subtype C gp140 Vaccine With MF59 AdjuvantSubtype C gp140 + MF59
02
Targets
CD4 (T lymphocyte surface antigen)HIV-1 envelope glycoprotein gp140 trimer
Beyond the preview
Go deeper on HIV-1 Subtype C gp140 vaccine + MF59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 Subtype C gp140 vaccine + MF59.